March 9, 2021
Rohto Pharmaceutical said on March 8 that it has commenced a Japanese PIIa clinical study of the JAK inhibitor ROH-201 (delgocitinib), which was discovered by Japan Tobacco, for patients with dry eyes including Sjogren’s syndrome. Rohto has been developing delgocitinib...read more